Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022.
Lidia GattoEnrico FranceschiAlicia TosoniVincenzo Di NunnoStefania BartoliniAlba Ariela BrandesPublished in: Expert opinion on drug discovery (2023)
GBM molecular heterogeneity and brain anatomical characteristics critically restrain drug effectiveness. Nevertheless, stimulating insights for future research and drug development come from innovative treatment strategies for GBM, such as multi-specific 'off-the-shelf' CAR-T therapy, oncolytic viral therapy and autologous dendritic cell vaccination. Disappointing results from targeted therapies-clinical trials are mainly due to complex interferences between signaling pathways and biological processes leading to drug resistance: hence, it is imperative in the future to develop combinatorial approaches and multimodal therapies.
Keyphrases
- dendritic cells
- clinical trial
- current status
- signaling pathway
- randomized controlled trial
- sars cov
- systematic review
- bone marrow
- single cell
- cell therapy
- regulatory t cells
- stem cells
- pain management
- mesenchymal stem cells
- resting state
- emergency department
- oxidative stress
- platelet rich plasma
- single molecule
- pi k akt
- immune response
- multiple sclerosis
- functional connectivity
- adverse drug
- induced apoptosis
- blood brain barrier
- electronic health record